By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ono Pharmaceutical Company, Ltd. 

2-1-5 Doshomachi
Chuo-ku
Osaka    541-8526  Japan
Phone: 06-6222-5551 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Merus (MRUS) Receives Milestone Payment From Ono Pharma (OPHLY) For Selection Of Bispecific Antibody Candidate For Clinical Development And Extends Partnership With CMC Service Agreement 10/19/2016 7:49:51 AM
Bristol-Myers Squibb (BMY)'s $4 Billion Disaster Sends Partner Ono Pharma (OPHLY)'s Stock Plunging 8/8/2016 6:34:42 AM
Celyad Hammers Out NKR-2 T-cell Immunotherapy Deal Worth $311.5 Million with Ono Pharma 7/11/2016 6:06:18 AM
How a $150,000 Drug Created with Bristol-Myers Squibb (BMY) Saved Ono Pharma 3/4/2016 7:06:29 AM
Ono Pharmaceutical Company, Ltd. Transforms Its High-Throughput Screening With Genedata AG Screener 2/23/2016 10:03:05 AM
Ono Pharmaceutical Company, Ltd. Selects Medidata To Power Clinical Trials Exploring Additional Cancer Indications For Immunotherapy Drug OPDIVO (Nivolumab) 1/27/2016 10:16:06 AM
Merus Reaches Pivotal Milestone In Bispecific Antibody Collaboration With Ono Pharmaceutical Company, Ltd. 4/8/2015 10:02:22 AM
Dako A/S (Acquired by Agilent Technologies, Inc.) (A) And Ono Pharmaceutical Company, Ltd. Announce Collaboration On Development Of PD-L1 Companion Diagnostic Test For Investigational Cancer Drug Opdivo(Nivolumab) 2/16/2015 8:53:21 AM
Ono Pharmaceutical Company, Ltd. And Gilead Sciences, Inc. (GILD) Announce Exclusive License Agreement To Develop BTK Inhibitor, ONO-4059, For The Treatment Of B-Cell Malignancies And Other Diseases 12/19/2014 11:44:30 AM
Ono Pharmaceutical Company, Ltd., Bristol-Myers Squibb Company (BMY), And Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (Nivolumab) And Mogamulizumab In Advanced Solid Tumors 12/10/2014 9:19:38 AM
123456
//-->